GlassScriptPhysician profile
Alexander E Fong
NPI 1326201658
$8,013.25
in general payments reported to CMS, 2019-2025
54 companies · $928 in 2025
The $928 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $625 · 2021: $1,656 · 2022: $1,568 · 2023: $1,045 · 2024: $1,512 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,485.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,767.25 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $698.22 | 2019-2025 | Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $422.93 | 2019-2025 | |
| Biogen, INC. | $333.58 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $248.39 | 2019-2024 | Rystiggo, Briviact |
| Genentech USA, INC. | $235.25 | 2019-2023 | Enspryng, Ocrevus |
| Biohaven Pharmaceuticals, INC. | $229.54 | 2020-2021 | |
| Argenx US, INC. | $224.48 | 2022-2025 | Vyvgart Hytrulo |
| Pfizer INC. | $218.66 | 2021-2025 | |
| Genzyme Corporation | $210.74 | 2019-2022 | |
| Allergan, INC. | $208.61 | 2019-2021 | |
| Celgene Corporation | $181.10 | 2021-2025 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $142.05 | 2020-2021 | |
| Amgen INC. | $135.63 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $126.47 | 2021-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Fong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.